小儿广朴止泻口服液治疗小儿腹泻的药物经济学评价

Pharmacoeconomic Evaluation of Xiaoerguangpuzhixie Oral Liquid in the Treatment of Infantile Diarrhea

目的对小儿广朴止泻口服液治疗小儿腹泻进行药物经济学评价。方法检索中国期刊全文数据库、万方数据知识服务平台、中文期刊全文数据库、Cochrane Library、EBASE等数据库,收集从2000年1月至2021年7月发表的关于小儿广朴止泻口服液治疗小儿腹泻的临床试验,观察组均在对照组常规治疗方案的基础上加用小儿广朴止泻口服液,治疗周期为3 d。效果指标为有效率或腹泻次数,核算治疗成本,计算增量成本-效果比(ICER)。结果本研究共纳入4篇文献,观察组治疗小儿腹泻的有效率均显著高于对照组(P<0.05),计算ICER得到以下结果:在常规治疗基础上加用小儿广朴止泻口服液较常规治疗在治疗小儿腹泻方面增加单位有效率,<1岁患儿需多花费1.4~2.3元,1~3岁患儿需多花费2.1~4.3元;在常规治疗基础上加用小儿广朴止泻口服液较常规治疗在治疗小儿腹泻方面每减少一次腹泻需要多花费3.8~11.4元。结论小儿广朴止泻口服液治疗小儿腹泻的临床疗效优于常规治疗,且对比常规治疗更具有成本经济效益。

Objective To analyze the pharmacoeconomics of Xiaoerguangpuzhixie Oral Liquid in the treatment of infantile diarrhea.Methods The clinical trials on the treatment of infantile diarrhea with a treatment period of 3 days were collected from January 2000 to July 2021 by searching the China National Knowledge Infrastructure,Wanfang Data Knowledge Service Platform,Cochrane Library,EBASE and other databases.Calculated the Incremental Cost-Effectiveness Ratio(ICER)by counting the effectiveness of treatment or the number of diarrhoea in the literature and accounting for the cost of treatment.Results A total of 4articles were included in this study,and the results showed the effective rate in observation group was higher than control group,the difference was statistically significant(P<0.05).It costs 1.4 to 4.3 yuan more to increase the efficiency per unit in the treatment of infantile diarrhea with Xiaoerguangpuzhixie Oral Liquid than with conventional treatment.It costs 3.8 to 11.4 yuan more to reduce one diarrhea in the treatment of infantile diarrhea with Xiaoerguangpuzhixie Oral Liquid than with conventional treatment.Conclusion The clinical effect of Xiaoerguangpuzhixie Oral Liquid in treating infantile diarrhea is better than that of conventional treatment,and it is more cost-effective than conventional treatment.